MX374851B - Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa - Google Patents

Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa

Info

Publication number
MX374851B
MX374851B MX2016014767A MX2016014767A MX374851B MX 374851 B MX374851 B MX 374851B MX 2016014767 A MX2016014767 A MX 2016014767A MX 2016014767 A MX2016014767 A MX 2016014767A MX 374851 B MX374851 B MX 374851B
Authority
MX
Mexico
Prior art keywords
lactate
dehydrogenase
regulating
expression
polypeptide production
Prior art date
Application number
MX2016014767A
Other languages
English (en)
Spanish (es)
Inventor
Amy Shen
Bradley Richard Snedecor
Chi Kin Domingos Ng
Meixia Zhou
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45004831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX374851(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX374851B publication Critical patent/MX374851B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/04—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a disulfide as acceptor (1.2.4)
    • C12Y102/04001—Pyruvate dehydrogenase (acetyl-transferring) (1.2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2016014767A 2010-05-28 2011-05-26 Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa MX374851B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34972710P 2010-05-28 2010-05-28
PCT/US2011/038191 WO2011150241A2 (en) 2010-05-28 2011-05-26 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase

Publications (1)

Publication Number Publication Date
MX374851B true MX374851B (es) 2025-03-06

Family

ID=45004831

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016014767A MX374851B (es) 2010-05-28 2011-05-26 Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa
MX2012013579A MX343604B (es) 2010-05-28 2011-05-26 Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.
MX2020009460A MX2020009460A (es) 2010-05-28 2012-11-22 Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2012013579A MX343604B (es) 2010-05-28 2011-05-26 Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.
MX2020009460A MX2020009460A (es) 2010-05-28 2012-11-22 Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.

Country Status (15)

Country Link
US (4) US9487809B2 (enExample)
EP (1) EP2576580B1 (enExample)
JP (3) JP6050226B2 (enExample)
KR (3) KR101989762B1 (enExample)
CN (1) CN102985437B (enExample)
BR (1) BR112012030197A2 (enExample)
CA (1) CA2800728C (enExample)
DK (1) DK2576580T3 (enExample)
ES (1) ES2599412T3 (enExample)
HU (1) HUE030820T2 (enExample)
MX (3) MX374851B (enExample)
PL (1) PL2576580T3 (enExample)
RU (1) RU2614125C2 (enExample)
SI (1) SI2576580T1 (enExample)
WO (1) WO2011150241A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2831860B2 (ja) 1991-03-29 1998-12-02 株式会社東芝 連続ラインの連続式冷却槽温度制御装置
EP2500413A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
US8895709B2 (en) 2008-10-20 2014-11-25 Abbvie Inc. Isolation and purification of antibodies using protein A affinity chromatography
CA2800728C (en) 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
SMT202100691T1 (it) 2013-07-11 2022-01-10 Modernatx Inc Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
SG10201800772TA (en) * 2013-10-11 2018-03-28 Regeneron Pharma Metabolically optimized cell culture
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015142903A2 (en) * 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
EP3666896A1 (en) 2014-10-10 2020-06-17 Dicerna Pharmaceuticals, Inc. Therapeutic inhibition of lactate dehydrogenase and agents therefor
KR102265924B1 (ko) * 2014-10-31 2021-06-15 삼성바이오에피스 주식회사 Pdk 불활성화에 의한 폴리펩타이드의 생산
WO2016125937A1 (ko) * 2015-02-06 2016-08-11 경북대학교 산학협력단 Pdk2를 이용한 여성 갱년기 질환 예방 또는 치료제의 스크리닝 방법 및 상기 방법으로 스크리닝 된 치료제를 유효성분으로 포함하는 여성 갱년기 질환의 예방 또는 치료용 약학적 조성물
CN105368839A (zh) * 2015-12-22 2016-03-02 中国人民解放军第三军医大学 一种有效抑制小鼠pdk2表达的rna干扰序列及其应用
EP3452080A4 (en) * 2016-05-02 2019-10-09 The Regents of the University of California MAMMALIAN CELLS WITHOUT LACTATE DEHYDROGENASE ACTIVITY
IL273875B2 (en) 2017-10-13 2025-07-01 Dicerna Pharmaceuticals Inc Methods and compositions for inhibiting expression of ldha
CN107904257B (zh) * 2017-11-22 2021-05-04 上海药明生物技术有限公司 一种增加cho细胞群蛋白表达量的方法
JP2021505662A (ja) 2017-12-04 2021-02-18 ザ ジェネラル ホスピタル コーポレイション 疾患を軽減するための細胞外酸化還元酵素系
EP3775184B1 (en) * 2018-03-29 2025-12-10 F. Hoffmann-La Roche AG Modulating lactogenic activity in mammalian cells
AU2020306672B2 (en) * 2019-06-26 2023-08-24 F. Hoffmann-La Roche Ag Mammalian cell lines with SIRT-1 gene knockout
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2021271317A1 (en) 2020-05-15 2023-01-19 Crispr Therapeutics Ag Messenger RNA encoding Cas9 for use in genome-editing systems
CN115948404B (zh) * 2023-02-01 2024-06-04 重庆医科大学 一种抑制环状RNA circPDHK1的siRNA及其用途
EP4574966A1 (en) * 2023-12-18 2025-06-25 Good Meat, Inc. Engineered cell lines for the production of cultivated meat

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
CA2113813C (en) 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ZA936128B (en) 1992-08-21 1995-02-20 Genentech Inc Method for treating a LFA-1 mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
DE69501817T2 (de) 1994-01-18 1998-09-10 Genentech Inc Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
EP1297847A3 (en) 1996-01-23 2003-05-07 Genentech, Inc. Anti-CD18 antibodies in stroke
US5726856A (en) 1996-02-28 1998-03-10 General Electric Company Hexasubstituted guanidinium salts and ultracapacitors employing them as electrolytes
US5714388A (en) 1996-08-14 1998-02-03 Bayer Corporation Apparatus and method for detecting chemiluminescent light
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DK1516629T3 (da) 1996-11-27 2013-06-03 Genentech Inc Humaniseret anti-CD-11a antibodies
BRPI9809387B8 (pt) 1997-04-07 2021-05-25 Genentech Inc anticorpo humanizado anti-fator de crescimento endotelial vascular humano e composição que o compreende
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2000078348A1 (en) 1999-06-17 2000-12-28 University Of Vermont And State Agricultural College Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells
CH694589A5 (de) 1999-06-25 2005-04-15 Genentech Inc Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern.
CA2387108A1 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
WO2002004598A2 (en) * 2000-07-12 2002-01-17 Immunex Corporation Improvement of cell culture performance by inhibitors of pyruvate dehydrogenase kinase
CA2921821A1 (en) * 2001-07-12 2003-01-23 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
US20090215860A1 (en) 2004-06-17 2009-08-27 The Regents Of The University Of California Compositions and methods for regulating gene transcription
CA2584057A1 (en) * 2004-10-08 2006-04-20 The Johns-Hopkins University Pyruvate dehydrogenase kinases as therapeutic targets for cancer and ischemic diseases
ES2591284T3 (es) 2007-08-07 2016-11-25 Chugai Seiyaku Kabushiki Kaisha Método para la producción de proteínas heterogéneas
AU2009257336B2 (en) * 2008-06-13 2016-01-28 Janssen Biotech, Inc. Methods for obtaining high viable cell density in mammalian cell culture
KR102018475B1 (ko) * 2008-09-15 2019-09-04 제넨테크, 인크. 세포 오스몰농도를 조절하기 위한 조성물 및 방법
CA2800728C (en) 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
JP2013531978A (ja) 2013-08-15
US20130084605A1 (en) 2013-04-04
KR101869987B1 (ko) 2018-07-20
US10704071B2 (en) 2020-07-07
WO2011150241A8 (en) 2012-12-06
DK2576580T3 (en) 2016-10-17
US10011856B2 (en) 2018-07-03
CA2800728A1 (en) 2011-12-01
KR101989762B1 (ko) 2019-06-14
MX343604B (es) 2016-11-11
CN102985437A (zh) 2013-03-20
JP2017074052A (ja) 2017-04-20
BR112012030197A2 (pt) 2015-09-29
US20190040435A1 (en) 2019-02-07
EP2576580A4 (en) 2014-07-02
RU2012157307A (ru) 2014-07-10
HUE030820T2 (en) 2017-06-28
KR20190067277A (ko) 2019-06-14
JP6325060B2 (ja) 2018-05-16
MX2020009460A (es) 2020-11-06
KR20180069130A (ko) 2018-06-22
US20200377919A1 (en) 2020-12-03
WO2011150241A2 (en) 2011-12-01
WO2011150241A3 (en) 2012-03-08
JP2018138030A (ja) 2018-09-06
SI2576580T1 (sl) 2016-12-30
ES2599412T3 (es) 2017-02-01
US20170191102A1 (en) 2017-07-06
EP2576580A2 (en) 2013-04-10
EP2576580B1 (en) 2016-09-14
KR20130077843A (ko) 2013-07-09
CA2800728C (en) 2020-10-27
US11046987B2 (en) 2021-06-29
PL2576580T3 (pl) 2017-03-31
US9487809B2 (en) 2016-11-08
MX2012013579A (es) 2013-01-24
JP6706642B2 (ja) 2020-06-10
CN102985437B (zh) 2016-05-25
RU2614125C2 (ru) 2017-03-22
JP6050226B2 (ja) 2016-12-21

Similar Documents

Publication Publication Date Title
MX374851B (es) Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa
EP2633036A4 (en) DIFFERENTIATION METHOD FOR THE PRODUCTION OF GLIA CELL POPULATIONS
NZ600585A (en) Expression of hexose kinase in recombinant host cells
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
MY193665A (en) Recombinant microorganisms and uses therefor
EP4379578A3 (en) Learning situations via pattern matching
EP2576801A4 (en) EXTRACTING A LIPID FROM CELLS AND PRODUCTS OBTAINED FROM THIS EXTRACTION
GB2513732A (en) Methods and compositions for sample identification
MX2014001383A (es) Colageno 7 y metodos relacionados.
BR112013025434A2 (pt) "cepas variantes de fundos filamentosos tendo modificação genética para maior produção de proteína tps2 e crescimento alterado e seu método de produção"
WO2012102527A3 (ko) 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
BR112015009042A8 (pt) Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa
EA201390592A1 (ru) Аллели 1-d-дезоксиксилулозо-5-фосфат синтазы, ответственные за усиленный биосинтез терпенов
MX2022002057A (es) Variantes de enzima con propiedades de ester sintasa mejoradas.
BR112013025430A2 (pt) "cepas variantes de fundos filamentosos tendo modificação genética para maior produção de proteína mpg1 e crescimento alterado e seu método de produção".
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
WO2012177983A3 (en) Microorganisms for producing ethylene glycol and methods related thereto
IN2015DN01812A (enExample)
EA201171144A1 (ru) ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
BR112013004419A2 (pt) fungos filamentosos que têm um fenótipo de viscosidade alterada.
MX390879B (es) Metodo de produccion con iones de cobre controlados.
BR112015014328A2 (pt) Célula de mamífero capaz de propagar arterivírus, cultura celular, e, método para a propagação de um arterivírus em cultura celular
MX2014012407A (es) Metodo para incrementar la secrecion de proteinas recombinantes.
WO2012100172A3 (en) Methods and compositions for the specific inhibition of hif-1a by double stranded rna
MX2013013063A (es) Plantas que tienen rasgos mejorados relacionados con el rendimiento y metodo para elaborar las mismas.